Bedside Genetic or Pharmacodynamic Testing to Prevent Periprocedural Myonecrosis During PCI (ONSIDE TEST)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 150 participants.

Also called NCT01930773

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 150 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01930773
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Hungary, Poland (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01930773. Randomized; no masking; primary purpose prevention. Start 2013-03 (registry gives no type); primary completion 2019-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Bedside Genetic or Pharmacodynamic Testing to Prevent Periprocedural Myonecrosis During PCI (ONSIDE TEST)
Acronym
ONSIDE TEST
Condition
Stable Angina
Intervention (Device)
Genotyping
Intervention (Device)
Phenotyping
Lead sponsor
Medical University of Warsaw (class: other)
Collaborator
Polish Cardiac Society (class: other)
Collaborator
University of Pecs (class: other)

Record details

Record id
cardio:ct-nct01930773
Content hash
a5a7ea82435693ed9066452577a8feb0b36ea76eb62af73e9ff4eb089459f7ec